MICIN
Active#44 in JapanEstimated valuation · Telemedicine and clinical trials · Japan
Provides online medical consultation, decentralised clinical-trial tools and digital insurance products that connect patients, hospitals and pharmaceutical companies in Japan.
Estimated valuation
AI · Japan ranking- Published valuation
- USD 101.5M · May 2026
- AI adjustment
- None
An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method
Uback rankings
How the AI ranks →| Ranking | Tier | Rank | Edition | Next update |
|---|---|---|---|---|
| Japan · all sectors | Top 50 | #44 | Edition 0 · October 2026 | 10 Jan 2027 |
Funding history
| Date | Round | Amount | Type | Investors |
|---|---|---|---|---|
| Oct 2023 | Series C | amount undisclosed | — | — |
Post-money about JPY 16.0bn (estimate incl. potential shares).
Rounds as cited by Uback’s rankings. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.
Independent analyses
By industry professionals & analystsIndustry professionals and financial analysts can publish their own analysis of MICIN as a PDF. It must answer at least one of these four questions, and stick to them:
Analyses are the opinion of their authors, not of Uback. They are checked before publication.
Comparable companies in Japan
Full Japan ranking →Last updated: Oct 2026Report an error
Uback is a content publisher and an aggregator of non-binding expressions of interest. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.